<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26799">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01988415</url>
  </required_header>
  <id_info>
    <org_study_id>STAR-114-SARA</org_study_id>
    <nct_id>NCT01988415</nct_id>
  </id_info>
  <brief_title>New Treatment Algorithm to Reduce Spherical Aberration After LASIK Correction for Myopia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Optics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to demonstrate that treatments generated by an
      investigational algorithm reduces spherical aberration compared to currently available
      iDesign treatments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Residual uncorrected power (spherical aberration)</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected and best-corrected distance visual acuity</measure>
    <time_frame>3 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Myopia</condition>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>Commercial Treatment Planning Software</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Approved treatment planning software</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VSS-Rx1 OPM software</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational treatment planning software</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VSS-Rx1 OPM software</intervention_name>
    <arm_group_label>VSS-Rx1 OPM software</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iDesign Advanced CustomVue wavefront-guided LASIK treatment</intervention_name>
    <arm_group_label>Commercial Treatment Planning Software</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at least 18 years of age at the time of preoperative exam

          -  Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better

          -  Demonstration of refractive stability

          -  Anticipated postoperative stromal bed thickness of at least 250 microns

          -  Willing and able to return for all study examinations

        Exclusion Criteria:

          -  Pregnant, breast-feeding, or intend to become pregnant over the course of the study

          -  Concurrent use of topical or systemic medications that may impair healing

          -  History of prior intraocular or corneal surgery, active ophthalmic disease, or other
             ocular abnormality

          -  Evidence of keratoconus, corneal irregularity, or abnormal topography in the
             operative eye(s)

          -  Known sensitivity or inappropriate responsiveness to any of the medications used in
             the postoperative course
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Tamayo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medico Oftalmologo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugenia Thomas, O.D.</last_name>
    <phone>714-247-8723</phone>
    <email>eugenia.thomas@amo.abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gustavo Tamayo, M.D.</name>
      <address>
        <city>Bogota Laser, Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>November 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Astigmatism</mesh_term>
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
